Zoetis Inc. (ZTS) Receives $67.93 Average PT from Brokerages
Zoetis Inc. (NYSE:ZTS) has earned a consensus recommendation of “Buy” from the nineteen analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $67.93.
A number of brokerages recently issued reports on ZTS. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a report on Thursday, October 12th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 price target on shares of Zoetis in a report on Wednesday, September 6th. BidaskClub downgraded Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Morgan Stanley upped their price target on Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Piper Jaffray Companies set a $73.00 price target on Zoetis and gave the company a “buy” rating in a report on Friday, August 25th.
Several hedge funds have recently bought and sold shares of ZTS. FineMark National Bank & Trust acquired a new stake in shares of Zoetis in the second quarter valued at approximately $210,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of Zoetis by 1.3% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after purchasing an additional 55 shares during the last quarter. Great West Life Assurance Co. Can raised its stake in shares of Zoetis by 23.1% during the second quarter. Great West Life Assurance Co. Can now owns 421,620 shares of the company’s stock worth $26,270,000 after purchasing an additional 79,163 shares during the last quarter. Bbva Compass Bancshares Inc. raised its stake in shares of Zoetis by 4.9% during the second quarter. Bbva Compass Bancshares Inc. now owns 6,029 shares of the company’s stock worth $376,000 after purchasing an additional 283 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS raised its stake in shares of Zoetis by 0.8% during the second quarter. Kornitzer Capital Management Inc. KS now owns 168,850 shares of the company’s stock worth $10,533,000 after purchasing an additional 1,385 shares during the last quarter. 93.33% of the stock is owned by institutional investors and hedge funds.
Zoetis (ZTS) traded up $0.12 during mid-day trading on Friday, hitting $70.97. 1,507,421 shares of the company were exchanged, compared to its average volume of 2,772,501. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. Zoetis has a 12-month low of $49.79 and a 12-month high of $72.79. The stock has a market capitalization of $34,607.21, a price-to-earnings ratio of 32.58, a price-to-earnings-growth ratio of 2.13 and a beta of 1.06.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.52 earnings per share. sell-side analysts forecast that Zoetis will post 2.37 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Thursday, November 9th were issued a $0.105 dividend. This represents a $0.42 annualized dividend and a dividend yield of 0.59%. The ex-dividend date of this dividend was Wednesday, November 8th. Zoetis’s payout ratio is currently 22.11%.
TRADEMARK VIOLATION NOTICE: This article was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/zoetis-inc-zts-receives-67-93-average-pt-from-brokerages/1748276.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.